Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

Published:2021-12 Issue:12 Volume:22 Page:1705-1720
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gay Francesca,Musto Pellegrino,Rota-Scalabrini Delia,Bertamini Luca,Belotti Angelo,Galli Monica,Offidani Massimo,Zamagni Elena,Ledda Antonio,Grasso Mariella,Ballanti Stelvio,Spadano Antonio,Cea Michele,Patriarca Francesca,D'Agostino Mattia,Capra Andrea,Giuliani Nicola,de Fabritiis Paolo,Aquino Sara,Palmas Angelo,Gamberi Barbara,Zambello Renato,Petrucci Maria Teresa,Corradini Paolo,Cavo Michele,Boccadoro Mario

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial;Perrot;Blood,2020

2. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial;Moreau;Blood,2016

3. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Moreau;Ann Oncol,2017

4. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

5. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial;Voorhees;Blood,2020

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review;The Oncologist;2024-09-05

2. Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database;Transplantation and Cellular Therapy;2024-09

3. Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs;Clinical and Experimental Medicine;2024-08-06

4. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial;The Lancet Oncology;2024-08

5. Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment—An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse;Clinical Lymphoma Myeloma and Leukemia;2024-08